Newsletter Tool

Today's Rundown

Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck's drug
Magellan Health partners with Zipline to deliver prescriptions by drone
Labcorp launches online platform for ordering at-home tests, scheduling in-person appointments
UPDATED: Sanofi's flu shots took a back seat to COVID-19 boosters late last year, and major job cuts still loom
The hits keep coming: Biogen's Aduhelm marketing, approval under fire in new FTC and SEC probes
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes
Medicare to cover at-home COVID-19 tests this spring after backlash from lawmakers
Tasso, Vault Health team up to provide at-home blood testing for siteless clinical trials
Regeneron projects no near-term sales of its blockbuster COVID-19 antibody given FDA action to ground it
From Amazon to New Balance, consumer brand execs bring 'outsider' perspective to healthcare
Ambu scores FDA clearance for single-use gastroscope and touchscreen display
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx

Featured Story

Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms

By Eric Sagonowsky

With Bristol Myers Squibb only a month away from biopharma's biggest loss of exclusivity this year, industry watchers are eager for any clues about how the company's new and future medicines will perform on the market. The drugmaker has already launched two new CAR-T products, Breyanzi and Abecma, and now it's busy scaling up on the manufacturing front in a bid to meet early demand.

Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck's drug

By Kyle LaHucik

Bayer will no longer work on eliapixant, an Evotec-partnered asset that was studied across four indications in midstage tests, including chronic cough. The companies will continue working together on other assets in phase 1, preclinical and discovery stages.

Magellan Health partners with Zipline to deliver prescriptions by drone

By Rebecca Torrence

Magellan Health plans to roll out a prescription delivery service via drone in partnership with Zipline, starting later this year in North Carolina for specialty and traditional medications.

Labcorp launches online platform for ordering at-home tests, scheduling in-person appointments

By Andrea Park

Building on the success of its direct-to-consumer COVID-19 testing options, Labcorp is supplanting its Pixel brand with a new platform that allows it to sidestep healthcare provider middlemen and enable individuals to order their own diagnostic tests.

UPDATED: Sanofi's flu shots took a back seat to COVID-19 boosters late last year, and major job cuts still loom

By Fraiser Kansteiner

While Sanofi's influenza business did gangbusters in Europe for the last three months of the year, the situation was different in the U.S. as the shifting COVID-19 vaccination landscape fueled a meaty sales decline. Meanwhile, Sanofi is still underway with an aggressive effort to slim down—and more cuts are coming in 2022.

The hits keep coming: Biogen's Aduhelm marketing, approval under fire in new FTC and SEC probes

By Fraiser Kansteiner

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen and its troubled Alzheimer’s med, the company revealed in a securities filing Thursday.

Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes

By Kyle LaHucik

Chicago biotech Exicure has a lot of soul searching to do as its CEO, chief medical officer, chief technology officer and three board members all hit the exit within a week. The biotech has no assets in human studies and will look to its pacts with Ipsen and AbbVie to save itself from further disaster.

PM Tracker

Featured Story

Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms

Top Stories

Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck's drug

Magellan Health partners with Zipline to deliver prescriptions by drone

Labcorp launches online platform for ordering at-home tests, scheduling in-person appointments

UPDATED: Sanofi's flu shots took a back seat to COVID-19 boosters late last year, and major job cuts still loom

The hits keep coming: Biogen's Aduhelm marketing, approval under fire in new FTC and SEC probes

Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes

Medicare to cover at-home COVID-19 tests this spring after backlash from lawmakers

Tasso, Vault Health team up to provide at-home blood testing for siteless clinical trials

Regeneron projects no near-term sales of its blockbuster COVID-19 antibody given FDA action to ground it

From Amazon to New Balance, consumer brand execs bring 'outsider' perspective to healthcare

Ambu scores FDA clearance for single-use gastroscope and touchscreen display

UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx